W

    WGRX (WGRX)

    Official site

    PHARMACEUTICAL RETAILERS

    $3.52
    +0.81 (+29.89%)

    Last updated: Jul 21, 2026 at 5:00 PM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Mar 26
    Reported May 19
    		$-3.24N/AN/ABeat-423.0%
    Dec 25
    Reported Mar 20
    		$-13.75N/AN/ABeat-15174.1%
    Sep 25
    Reported Nov 19
    		$-0.46N/AN/ABeat-
    Jun 25
    Reported Aug 19
    		$-0.11N/AN/ABeat-
    Mar 25
    Reported May 12
    		$-0.62N/AN/ABeat-
    Dec 24
    Reported Mar 25
    		$-0.09$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit MarginN/AOperating MarginN/A
    ROEN/AROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current RatioN/AQuick RatioN/A
    Trading Statistics
    BetaN/AAvg VolumeN/A
    52-Week HighN/A52-Week LowN/A

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.91
    SMA 20$2.96
    SMA 50$3.80
    SMA 200$15.08
    EMA 10$2.96
    EMA 20$3.09
    EMA 50$4.02
    EMA 200$21.90

    MACD

    Line: -0.24Signal: -0.33Hist: 0.09

    ADX

    ADX: 22.0+DI: 18.5-DI: 8.8

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down88.0
    PSAR$2.48

    Bollinger Bands

    Upper Band$3.35
    Lower Band$2.57
    %B Position2639%(Upper)
    Band Width1.22

    RSI (14-Day)

    Neutral
    55.1

    Momentum Oscillators

    Stoch %K40.7
    Stoch %D25.4
    Williams %R-20.7
    ROC (10d)18.1%
    Momentum0.54
    CCI (20d)203.1
    MFI (14d)83.0

    Volatility Measures

    ATR (14d)$0.64(18.3%)
    StdDev (20d)0.20
    Hist Vol128.2%(High)

    Volume Flow

    VWAP$3.34
    OBV1.7B
    AD Line942.2B
    CMF (20d)0.145

    Volume Metrics

    Avg Vol (20d)46.7K
    Vol Ratio11.8x(High)
    VWMA (20d)$3.28

    Pivot Points

    R3$2.93
    R2$2.86
    R1$2.79
    Pivot Point$2.72
    S1$2.65
    S2$2.58
    S3$2.51

    Advanced Oscillators

    TSI-16.34
    Ultimate Osc48.9
    KST-212.05

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.78M$1.56M$1.67M$3.01M$7.79M$10.86M$12.41M$5.67M$44,540$0$34.37M$-44,540
    Cost of Revenue$1.60M$1.39M$9.53M$2.78M$7.29M$10.17M$11.16M$5.15M$47,148$0$31.60M$-47,148
    Gross Profit$182,204$170,221$-7,855,824$231,012$505,752$692,641$1.25M$521,244$-2,608$0$2.77M$2,608
    Operating Expenses$7.53M$6.20M$17.50M$31.78M$6.01M$32.04M$5.00M$2.27M$570,408$79,764$13.09M$903,312
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$7.06M$4.87M$4.13M$30.17M$4.86M$31.17M$4.35M$1.80M$570,408$79,764$8.30M$1.17M
    Operating Income$-7,345,054$-6,015,538$-25,352,024$-31,548,329$-5,500,376$-31,348,368$-3,747,532$-1,744,820$-573,016$-79,764$-10,316,688$-903,312
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$10.44M$1.81M$2.51M$2.78M$1.18M$1.09M$689,186$137,614$1,309$3,358$1.58M$4,667
    Income Before Tax$-18,363,225$-7,742,597$-27,852,959$-34,318,204$-6,672,464$-32,430,903$-4,331,752$-1,867,027$-574,325$-83,122$-11,797,164$-903,312
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-18,363,225$-7,742,597$-27,852,959$-34,318,204$-6,672,464$-32,430,903$-4,331,752$-1,867,027$-574,325$-83,122$-11,797,163$-903,312
    EBITDA$-6,706,060$-4,074,356$-24,946,751$-30,330,067$-4,674,324$-30,511,435$-2,995,325$-1,274,784$-560,222$-79,764$-5,426,838$-903,312
    EBIT$-7,920,291$-5,916,798$-25,342,981$-31,539,234$-5,488,424$-31,336,413$-3,642,566$-1,729,413$-573,016$-79,764$-10,218,557N/A
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about WGRX

    News

    DataMeds AI, Inc. (Nasdaq: MEDS) details 34,462,058-share resale

    DataMeds AI, Inc. (Nasdaq: MEDS) has filed an S-1 registration statement detailing the resale of up to 34,462,058 shares of common stock by existing selling stockholders. These shares originate from previously issued stock, convertible notes from May 2026, and various warrants. The company itself will not sell shares or receive proceeds from these resales, but may receive cash from future warrant exercises. The filing highlights potential significant dilution for existing shareholders due to variable conversion prices and low floor prices on convertible instruments.

    Stock Titan•8/7/26•
    Neutral

    DataMEDS AI (WGRX) LOI could give new partners 84.6% ownership stake

    DataMEDS AI, Inc. (WGRX) has entered into an Amended and Restated Letter of Intent with several partners to negotiate a stock-based transaction. This potential deal involves acquiring or licensing intellectual property, expanding existing licenses, and obtaining a controlling interest in Tollo Health, LLC. If completed, new investors and partners are expected to collectively hold approximately 84.6% of DataMEDS AI's common stock, significantly reshaping its ownership structure and management.

    Stock Titan•8/4/26•
    Neutral

    Wellgistics Health Terminates Equity Line of Credit to Further Support Growth Strategy

    Wellgistics Health Inc. (NASDAQ:WGRX) has announced the termination of its equity purchase agreement with Hudson Global Ventures, LLC, a strategic move to shift towards accretive financing and reinforce long-term shareholder value. The decision was driven by strong execution in expanding its pharmacy network and accelerating AI-powered prescription routing technology adoption. The company aims to optimize its capital structure and pursue more favorable funding opportunities to support its growth trajectory and focus on operational strength.

    Democrat and Chronicle•7/28/26•
    Bullish

    Wellgistics Health Selects Top Five Blockchain Platforms to Initiate Patent Protected PharmacyChain(TM) Smart Contracts-enabled Pharmaceutical Drug Tracking System to Support Industry-wide Serialization Mandate

    Wellgistics Health, Inc. has chosen Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu, and Corda (R3) as the top five blockchain platforms to develop its patent-protected PharmacyChain™ system. This system will utilize smart contracts to track pharmaceutical drugs, supporting industry-wide serialization mandates like the DSCSA. The company aims to integrate this technology within its own pharmacy by the end of Q2 2026 and eventually offer it to its network of over 6,500 independent pharmacies and other major industry participants, leveraging its intellectual property to improve pharmaceutical supply chain management and transparency.

    www.marketscreener.com•7/24/26•
    Bullish

    RPR secures Wellgistics Health comms brief

    Rubenstein Public Relations (RPR) has been appointed as the agency of record for Wellgistics Health, Inc., a health technology company listed on NASDAQ under WGRX. RPR will lead a communications campaign focusing on thought leadership, corporate positioning, and promoting Wellgistics Health's AI-integrated healthcare ecosystem and licensed technologies. Wellgistics Health, known for its EinsteinRx AI platform, is developing "Health Lives Here" mobile app to consolidate patient health data and improve access to care.

    https://marketingreport.one/•7/24/26•
    Bullish

    Frequently Asked Questions About WGRX

    Does WGRX pay dividends?
    WGRX (WGRX) does not currently pay a regular dividend.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In